On 9 May, GE Healthcare introduced, at the Heart Rhythm Society’s (HRS) 34th Annual Scientific Sessions, the Innova EPVision 2.0 an application that combines information from EP recording and live fluoroscopy, and Dose Blueprint, a comprehensive dose management strategy helping clinicians achieve in particular 50% dose reduction on Innova IGS single plane systems compared to previous releases.
Innova EPVision 2.0
According to a company release, Innova EPVision 2.0 provides live visualisation of anatomy and devices during procedures where traditional mapping systems may not be effective for use, or where enhanced visualisation is desirable but the additional cost of a mapping procedure may not be justified. This innovation enables a new procedure called “Image guided point tagging.” This novel technique fuses cardiac models on live fluoroscopy and colour codes them with activation intervals using CardioLab signal data. For GE customers using CardioLab and Innova, this new functionality expands the capabilities and enhances the versatility of systems in the lab.
“Innova EPVision 2.0 is an application that combines information from EP recording, live fluoroscopy and cardiac models, providing advanced visualisation to help clinicians perform procedures in EP where traditional mapping systems are not indicated, or may be ineffective,” said Jean-Michel Milles, general manager, Cardiovascular, GE Healthcare. “Since every EP lab has recording and fluoroscopy, GE customers with CardioLab and Innova can now realise the benefits of real-time navigation in 3D models, including tagging structures with colour-coded activation times, without incurring the additional cost of specialised supplies.”
When a complex EP procedure is performed using emerging technologies such as Cryoballoon, or left atrial appendage devices, traditional mapping systems do not help visualisation since impedance-based and magnetic localisation systems rely on the presence of EP diagnostic catheters or catheters with magnetic sensor coils. Innova EPVision 2.0 provides accurate visualisation of the anatomy and the devices for these procedures where traditional mapping systems may be ineffective.
Additionally, during standard anatomic ablations where anatomic visualisation is required without activation mapping, such as pulmonary vein isolations (PVI), Innova EPVision 2.0 provides accurate visualisation of anatomy and devices without the need for specialised catheters or patches.
For procedures such as typical flutters, atrioventricular reciprocating tachycardia, atrioventricular nodal reentry tachycardia and Wolff-Parkinson-White procedures, physicians need better visualisation of the catheter position, including the ability to tag a spot to return to later. Innova EPVision 2.0 provides enhanced visualisation and tagging capabilities not available via fluoroscopy alone.
New dose reduction technologies
GE is also advancing the ability for clinicians to manage their dose more effectively during long EP procedures using new features on Innova and with a comprehensive dose-management strategy called the GE Blueprint.
New low-dose imaging protocols launched at HRS this year include a new lower frame rate that gives users an additional exposure rate option with a 50% dose rate reduction compared to previous versions.
DoseMap, a recent addition to GE Healthcare’s comprehensive portfolio of dose management solutions, also aims to help address such challenges in complex interventions. With DoseMap, clinicians can visualise cumulated local patient dose throughout the examination. The dose distribution is projected on a patient body model and the resulting dose distribution map is displayed on the reference monitor next to the live image. This empowers the physician with timely dose information without disrupting their procedure workflow.
